

**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

<b>Application Number</b>	10/579,500
<b>Filing Date</b>	Sept. 15, 2006
<b>First Named Inventor</b>	Mehta et al.
<b>Art Unit</b>	1642
<b>Examiner Name</b>	Goddard, Laura B.
<b>Attorney Docket No.</b>	10589-096-999

**U.S. PATENT DOCUMENTS**

*Examiner Initials	Cite No.	Document Number – Kind Code	Publication Date mm/dd/yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A01	2002/0006661	01/17/02	Green et al.	
	A02	2002/0132257	09/19/02	Giordano et al.	
	A03	2003/0135870	07/17/03	Cheikh et al.	
	A04	2003/0199453	10/23/03	Giordano et al.	
	A05	2004/0063120	04/01/04	Beer et al.	
	A06	2004/0091866	05/13/04	Giordano et al.	
	A07	2004/0138282	07/15/04	Greig et al.	
	A08	2004/0152117	08/05/04	Giordano et al.	
	A09	2004/0231007	11/18/04	Kastelic et al.	
	A10	2007/0111203	05/17/07	Cao et al.	
	A11	2009/0068654	03/12/09	Kastelic et al.	
	A12	3,346,381	10/10/67	Grieg	
	A13	5,439,797	08/08/95	Tsien et al.	
	A14	5,444,149	08/22/95	Keene et al.	
	A15	5,587,300	12/24/96	Malter	
	A16	5,691,145	11/25/97	Pitner et al.	
	A17	5,698,427	12/16/97	Keene et al.	
	A18	5,700,660	12/23/97	Leonard et al.	
	A19	5,731,343	03/24/98	Feng et al.	
	A20	5,776,738	07/07/98	Dell'Orco, Sr. et al.	
	A21	5,843,770	12/01/98	Ill et al.	
	A22	5,849,520	12/15/98	Leonard et al.	
	A23	5,859,227	01/12/97	Giordano et al.	
	A24	5,908,779	06/01/99	Carmichael et al	
	A25	5,928,888	07/17/99	Whitney	
	A26	5,990,298	11/23/99	Carmichael et al	
	A27	6,004,749	12/21/99	Giordano et al.	

NYI-4181623v1

**EXAMINER  
SIGNATURE**

**DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

<b>Application Number</b>	10/579,500
<b>Filing Date</b>	Sept. 15, 2006
<b>First Named Inventor</b>	Mehta et al.
<b>Art Unit</b>	1642
<b>Examiner Name</b>	Goddard, Laura B.
<b>Attorney Docket No.</b>	10589-096-999

**U.S. PATENT DOCUMENTS**

*Examiner Initials	Cite No.	Document Number – Kind Code	Publication Date mm/dd/yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A28	6,057,437	05/02	Kamiya et al.	
	A29	6,107,029	08/22/00	Giordano	
	A30	6,159,709	12/12/00	Korneluk et al.	
	A31	6,171,821	01/09/01	Korneluk et al.	
	A32	6,214,563	04/10/01	Negulescu et al.	
	A33	6,221,587	04/27/01	Ecker et al.	
	A34	6,221,612	04/24/01	Knapp et al.	
	A35	6,232,070	05/05/01	Shuman	
	A36	6,265,167	07/24/01	Carmichael et al.	
	A37	6,265,546	07/24/01	Cohen et al.	
	A38	6,303,295	10/16/01	Taylor et al.	
	A39	6,331,170	12/18/01	Ordway	
	A40	6,331,396	12/18/01	Silverman et al.	
	A41	6,399,373	06/04/02	Bougueleret	
	A42	6,448,007	09/10/02	Giordano et al.	
	A43	6,455,280	09/24/02	Edwards et al.	
	A44	6,476,208	11/05/02	Cohen et al.	
	A45	6,617,493	09/09/03	Fader	
	A46	6,627,797	09/30/03	Duvick et al.	
	A47	6,635,671	10/21/03	Kastelic et al.	
	A48	6,638,522	10/28/03	Mulye	
	A49	6,645,747	11/11/03	Hallahan et al.	
	A50	6,653,132	11/25/03	Keshet et al.	
	A51	6,667,152	12/23/03	Miles et al.	
	A52	6,872,850	03/29/05	Giordano et al.	
	A53	7,078,171	07/18/06	Giordano et al.	

NYI-4181623v1

**EXAMINER  
SIGNATURE**

**DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

<b>Application Number</b>	10/579,500
<b>Filing Date</b>	Sept. 15, 2006
<b>First Named Inventor</b>	Mehta et al.
<b>Art Unit</b>	1642
<b>Examiner Name</b>	Goddard, Laura B.
<b>Attorney Docket No.</b>	10589-096-999

**FOREIGN PATENT DOCUMENTS**

*Examiner Initials	Cite No.	Foreign Patent Document Country Code, Number, Kind Code (if known)	Publication Date mm/dd/yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	B01	EP 1176196	01/30/02	Message Pharmaceuticals, Inc.		
	B02	EP 1 604 011	12/14/05	PTC Therapeutics, Inc.		
	B03	EP 1 761 638	03/14/07	PTC Therapeutics, Inc.		
	B04	GB 9828707.1	12/24/98	Novartis AG		
	B05	GB 9828709.7	12/24/98	Novartis AG		
	B06	WO 93/20212	10/14/99	Government of the United States of America, as represented by the Secretary, Department of Health and Human Services		
	B07	WO 95/33831	12/14/95	Creative Biomolecules Inc.		
	B08	WO 98/39484	09/11/98	Scriptgen Pharmaceuticals, Inc.		
	B09	WO 00/39314	07/06/00	Novation Pharmaceuticals, Inc.		
	B10	WO 01/084155	08/11/01	Message Pharmaceuticals, Inc.		
	B11	WO 02/048150	06/20/02	The Government of the United States of America		
	B12	WO 03/087815	10/23/03	Novartis AG		
	B13	WO 05/049868	06/02/05	PTC Therapeutics, Inc.		
	B14	WO 05/095615	10/13/05	Novation Pharmaceuticals, Inc.		
	B15	WO 05/118857	12/15/05	PTC Therapeutics, Inc.		
	B16	WO 06/022712	03/02/06	PTC Therapeutics, Inc.		

**NON PATENT LITERATURE DOCUMENTS**

Cite No.	Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
C01	ADAMS et al., 1991, "Fluorescence ratio imaging of cyclic AMP in single cells" Nature 349:694-697	
C02	AFOUDA et al., 1999, "Localized XId3 mRNA activation in Xenopus embryos by cytoplasmic polyadenylation" Mech Dev 88(1):15-31	
C03	AHARON & SCHNEIDER, 1993, "Selective destabilization of short-lived mRNAs with the granulocyte-macrophage colony-stimulating factor AU-rich 3' noncoding region is mediated by a cotranslational mechanism" Mol. Cell. Biol. 13: 1971-1980	

NYI-4181623v1

**EXAMINER  
SIGNATURE**

**DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

<b>Application Number</b>	10/579,500
<b>Filing Date</b>	Sept. 15, 2006
<b>First Named Inventor</b>	Mehta et al.
<b>Art Unit</b>	1642
<b>Examiner Name</b>	Goddard, Laura B.
<b>Attorney Docket No.</b>	10589-096-999

**NON PATENT LITERATURE DOCUMENTS**

	<b>Cite No.</b>	<b>Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.</b>	<b>T</b>
	C04	AKASHI et al., 1994, "Number and location of AUUUA motifs: Role in regulating transiently expressed RNAs." Blood 83:3182-3187 Am Soc. Of Hemat.	
	C05	AKIRI et al., 1998, "Regulation of vascular endothelial growth factor (VEGF) expression is mediated by Internal initiation of Translation and Alternative Initiation of Transcription" Oncogene 17:227-236	
	C06	AMARA et al., 1999, "TGF-beta(1), regulation of Alzheimer amyloid precursor protein mRNA expression in a normal human astrocyte cell line: mRNA stabilization." Brain Res. Mol. Brain Res. 71(1):42-49	
	C07	AUWERX, 1991, "The human leukemia cell line, THP-1: A multifaceted model for the study of monocyte-macrophage differentiation." Experientia 47:22-31 Birkhauser Verlag Basel	
	C08	BANHOLZER et al., 1997, "Rapamycin destabilizes interleukin-3 mRNA in autocrine tumor cells by a mechanism requiring an intact 3' untranslated region." Molecular and Cellular Biology 17: 3254-3260	
	C09	BARDONI & MANDEL, 2002, "Advances in understanding of fragile X pathogenesis and FMRP function, and in identification of X linked mental retardation genes." Curr. Opin. Genet. Dev. 12(3):284-293	
	C10	BARKOFF et al., 2000, "Translational control of cyclin B1 mRNA during meiotic maturation: coordinated repression and cytoplasmic polyadenylation" Dev Biol. 220(1):97-109	
	C11	BASHAW & BAKER, 1995, "The msl-2 dosage compensation gene of Drosophila encodes a putative DNA-binding protein whose expression is sex specifically regulated by Sex-lethal." Develop. 121(10):3245-3258.	
	C12	BEELMAN & PARKER, 1994, "Differential effects of translational inhibition in cis and in trans on the decay of the unstable yeast MFA2 mRNA." J. Biol. Chem, 269:9687-9692	
	C13	BENJAMIN et al., 1997, "Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal." Proc. Natl. Acad Sci 94:8761-8766	
	C14	BERGSTEN & GAVIS, 1999, "Role for mRNA localization in translational activation but not spatial restriction of nanos RNA." Develop. 126(4):659-669	
	C15	BEUTLER et al., 1988, "Assay of ribonuclease that preferentially hydrolyses mRNAs containing cytokine-derived UA-rich instability sequences." Biochem. Biophys Res. Commun. 152:973-980	
	C16	BHATTACHARYYA et al., 2007, "Mining the GEMS – a novel platform technology targeting post-transcriptional control mechanisms" Drug Discovery Today 12(13-14):553-560	
	C17	BOCK et al., 1992, "Selection of single-stranded DNA molecules that bind and inhibit human thrombin." Nature 355:564-566	
	C18	BORNES et al., 2004, "Control of the Vascular Endothelial growth factor internal ribosome entry site (IRES) Activity and translation initiation by Alternatively Spliced Coding sequences." J Biol. Chem. 279(18):18717-18726	
	C19	BRENCHLEY, 1998, "Antagonizing the expression of VEGF in pathological angiogenesis," Exp. Opin Ther. Patents 8(12): 1695-1706	
	C20	BRENNAN & STEITZ, 2001, "HuR and mRNA stability." Cell. Mol. Life. Sci. 58:266-277	
	C21	CAO, "Develop New cancer drugs that control VEGF expression: VEGF is an endothelial cell specific mitogen." Grant application	

NYI-4181623v1

**EXAMINER  
SIGNATURE**

**DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

<b>Application Number</b>	10/579,500
<b>Filing Date</b>	Sept. 15, 2006
<b>First Named Inventor</b>	Mehta et al.
<b>Art Unit</b>	1642
<b>Examiner Name</b>	Goddard, Laura B.
<b>Attorney Docket No.</b>	10589-096-999

**NON PATENT LITERATURE DOCUMENTS**

	<b>Cite No.</b>	<b>Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.</b>	<b>T</b>
	C22	CAO, "Targeting VEGF 5'-and 3'-UTRs for tumor therapy: generation of stable cell lines for High Throughput screening."	
	C23	CARBALLO et al., 1998, "Feedback inhibition of macrophage tumor necrosis factor-alpha production by tristetraprolin." Science 281:1001-1005	
	C24	CASTAGNETTI et al., 2000, "Control of oskar mRNA translation by Bruno in a novel cell-free system from Drosophila ovaries." Develop. 127(5):1063-1068	
	C25	CHARLESWORTH et al., 2000, "The temporal control of Wee1 mRNA translation during Xenopus oocyte maturation is regulated by cytoplasmic polyadenylation elements within the 3'-untranslated region." Dev. Biol. 227(2): 706-719	
	C26	CHEN et al., 1994, "Interplay of two functionally and structurally distinct domains of the c-fos AU-rich element specifies its mRNA-destabilizing function." Mol. Cell. Biol. 14:416-426	
	C27	CHEN et al., 1994, "Selective degradation of early-response-gene mRNAs: Functional analyses of sequence features of the AU-rich elements." Mol. Cell. Biol. 14: 8471-8482	
	C28	CHEN et al., 1995, "AU-rich elements: characterization and importance in mRNA degradation" Trends Biochem. Sci. 20:465-470	
	C29	CHEN et al., 1995, "mRNA decay mediated by two distinct AU-rich elements from c-fos and granulocyte-macrophage colony-stimulating factor transcripts: different deadenylation kinetics and uncoupling from translation." Mol. Cell. Biol. 15:5777-5788	
	C30	CHEN et al., 2001, "AU binding proteins recruit the exosome to degrade ARE-containing mRNAs" Cell 107:451-464	
	C31	CHO et al., 2002, "Emerging techniques for the discovery and validation of therapeutic targets for skeletal diseases" Expert Opin. Ther. Targets 6(6):679-689	
	C32	CLAFFEY et al., 1998, "Identification of a human VPF/VEGF 3' untranslated region mediating hypoxia-induced mRNA stability." Mol. Biol. Cell. 9:469-481	
	C33	CLARK et al., 2000, "Synthesis of the posterior determinant Nanos is spatially restricted by a novel cotranslational regulatory mechanism." Curr. Biol. 10(20):1311-1314	
	C34	CLARK et al., 2002, "A common translational control mechanism functions in axial patterning and neuroendocrine signaling in Drosophila." Develop. 129(14): 3325-3334	
	C35	COHEN et al., 1996, "CN1-1493 inhibits monocyte/macrophage tumor necrosis factor by suppression of translation efficiency." Proc. Natl. Acad. Sci. USA 93:3967-3971	
	C36	CRAWFORD et al., 1997, "The role of 3' poly (A) tail metabolism in tumor necrosis factor- $\alpha$ regulation," J. Biol. Chem. 272:21120-21127. The Am Soc of Biochem. And Molec. Biol.	
	C37	CROSIO et al., 2000, "La protein has a positive effect on the translation of TOP mRNAs in vivo." Nucl. Acids. Res. 28(15):2927-34	
	C38	CRUCS et al., 2000, "Overlapping but distinct RNA elements control repression and activation of nanos translation." Mol. Cell. 5(3):457-467	
	C39	CURATOLA et al., 1995, "Rapid degradation of AU-rich element (ARE) mRNAs is activated by ribosome transit and blocked by secondary structure at any position 5' to the ARE." Mol. Cell. Biol. 15:6331	

NYI-4181623v1

**EXAMINER  
SIGNATURE**

**DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)	<b>Application Number</b>	10/579,500
	<b>Filing Date</b>	Sept. 15, 2006
	<b>First Named Inventor</b>	Mehta et al.
	<b>Art Unit</b>	1642
	<b>Examiner Name</b>	Goddard, Laura B.
	<b>Attorney Docket No.</b>	10589-096-999

### NON PATENT LITERATURE DOCUMENTS

	<b>Cite No.</b>	<b>Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.</b>	<b>T</b>
	C40	DAHANUKAR & WHARTON, 1996, "The Nanos gradient in Drosophila embryos is generated by translational regulation." Genes Dev 20:2610-2620	
	C41	DANNER et al., 1998, "Agonist regulation of human beta <sub>2</sub> -adrenergic receptor mRNA stability occurs via a specific AU-rich element," J. Biol. Chem. 273(6):3223-3229	
	C42	DATABASE WPI Week, 2002, "Screening drug improving insulin resistance without exacerbating diabetic retinopathy, by detecting expression of reporter gene fused to promoter region of human vascular endothelial growth factor gene in mammal cell." JP 2001 340080 A	
	C43	DE JONG et al., 2002, "RNA and RNA-protein complexes as targets for therapeutic intervention", Curr. Topics Medicinal Chem. 2:289-302	
	C44	DE WET et al., 1987, "Firefly Luciferase Gene: Structure and Expression in Mammalian Cells." Molec & Cell. Biol. 7(2):725-737	
	C45	DIAS et al., 1994, "Chemical probe for glycosidic conformation in telomeric DNAs " J. Am. Chem. Soc. 116:4479-4480	
	C46	CHILD et al., 1999, "Cell type-dependent and -independent control of <i>HER-2/neu</i> translation" Int Journal of Biochem & Cell Biol 31:201-213	
	C47	DOMINSKI & MARZLUFF, 1999, "Formation of the 3' end of histone mRNA." Gene 239(1):1-14	
	C48	DREYFUSS et al., 2002 "Messenger-RNA-Binding Proteins and the Messages they carry," Nature Rev Molec cell Biol. 3:195-205	
	C49	EIBL et al., 1999, "In vivo analysis of plastid psbA, rbcL and rpl32 UTR elements by chloroplast transformation: tobacco plastid gene expression is controlled by modulation of transcript levels and translation efficiency", Plant J. 19:333-345	
	C50	FAN et al., 1998, "Overexpression of HuR, a nuclear-cytoplasmic shuttling protein, increases the <i>in vivo</i> stability of ARE-containing mRNAs." EMBO J 17:3448-3460	
	C51	FORSYTHE et al., 1996, "Activation of Vascular endothelium growth factor gene transcription by Hypoxia-Inducible Factor 1" Molec & Cell Biol. 16(9):4604-4613	
	C52	FORTES et al., 2003, "Inhibiting expression of specific genes in mammalian cells with 5' end-mutated u1 small nuclear RNAs targeted to terminal exons of pre-mRNA" Proc. Natl. Acad. Sci 100(14):8264-8269	
	C53	MEHTA et al, 2006, "Derepression of the Her-2 uORF is mediated by a novel post-transcriptional control mechanism in cancer cells." Genes & Dev, 20:939-953	
	C54	GAN et al., 1998, "Functional characterization of the internal ribosome entry site of eIF4G mRNA" J. Biol. Chem. 273:5006-5012	
	C55	GAVIS et al., 1996, "A conserved 90 nucleotide element mediates translational repression of nanos RNA. Development. 1996 Sep;122(9):2791-800. " Develop. 122(9):2791-2800	
	C56	GEBAUER et al., 1998, "The Drosophila splicing regulator sex-lethal directly inhibits translation of male-specific-lethal 2 mRNA" RNA 4(2):142-150	
	C57	GENBANK Accession No: AF022375, dated 10/7/1998	
	C58	GENBANK Accession No: AJ131730, dated 4/15/2005	

NYI-4181623v1

**EXAMINER  
SIGNATURE**
**DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

<b>Application Number</b>	10/579,500
<b>Filing Date</b>	Sept. 15, 2006
<b>First Named Inventor</b>	Mehta et al.
<b>Art Unit</b>	1642
<b>Examiner Name</b>	Goddard, Laura B.
<b>Attorney Docket No.</b>	10589-096-999

**NON PATENT LITERATURE DOCUMENTS**

	<b>Cite No.</b>	<b>Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.</b>	<b>T</b>
	C59	GENBANK Accession No: M11567, dated 10/30/1994	
	C60	GENBANK Accession No: M14745, dated 4/27/1993	
	C61	GENBANK Accession No: M14758, dated 12/3/1999	
	C62	GENBANK Accession No: M33680, dated 8/3/1993	
	C63	GENBANK Accession No: M54968, dated 2/4/1997	
	C64	GENBANK Accession No: M90100, dated 12/31/1994	
	C65	GENBANK Accession No: NM_0002 30, dated 3/5/2006	
	C66	GENBANK Accession No: NM_0001 62, dated 1/15/2006	
	C67	GENBANK Accession No: NM_000134, dated 10/15/2006	
	C68	GENBANK Accession No: NM_0002 08, dated 2/24/2006	
	C69	GENBANK Accession No: NM_0002 47, dated 2/27/2006	
	C70	GENBANK Accession No: NM_0003 21, dated 3/5/2006	
	C71	GENBANK Accession No: NM_0004 18, dated 2/12/2006	
	C72	GENBANK Accession No: NM_0005 27, dated 1/15/2006	
	C73	GENBANK Accession No: NM_0005 72, dated 3/5/2006	
	C74	GENBANK Accession No: NM_0005 89, dated 3/5/2006	
	C75	GENBANK Accession No: NM_0006 65, dated 2/28/2006	
	C76	GENBANK Accession No: NM_000600, dated 3/5/2006	
	C77	GENBANK Accession No: NM_0007 58, dated 2/12/2006	
	C78	GENBANK Accession No: NM_0007 84, dated 11/27/2005	
	C79	GENBANK Accession No: NM_0007 91, dated 11/6/2005	
	C80	GENBANK Accession No: NM_0007 99, dated 1/29/2006	
	C81	GENBANK Accession No: NM_000794, dated 9/17/2006	
	C82	GENBANK Accession No: NM_0008 99, dated 11/27/2005	
	C83	GENBANK Accession No: NM_0008 ev 75, dated 4/10/2009	
	C84	GENBANK Accession No: NM_0009 48, dated 2/26/2006	
	C85	GENBANK Accession No: NM_0011 45, dated 3/5/2006	

NYI-4181623v1

**EXAMINER  
SIGNATURE**

**DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

<b>Application Number</b>	10/579,500
<b>Filing Date</b>	Sept. 15, 2006
<b>First Named Inventor</b>	Mehta et al.
<b>Art Unit</b>	1642
<b>Examiner Name</b>	Goddard, Laura B.
<b>Attorney Docket No.</b>	10589-096-999

**NON PATENT LITERATURE DOCUMENTS**

	<b>Cite No.</b>	<b>Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.</b>	<b>T</b>
	C86	GENBANK Accession No: NM_001168, dated 3/5/2006	
	C87	GENBANK Accession No: NM_0012 40, dated 2/26/2006	
	C88	GENBANK Accession No: NM_0015 65, dated 1/29/2006	
	C89	GENBANK Accession No: NM_0015 67, dated 1/29/2006	
	C90	GENBANK Accession No: NM_0017 28, dated 2/26/2006	
	C91	GENBANK Accession No: NM_0017 ev 25, dated 10/22/2006	
	C92	GENBANK Accession No: NM_001917, dated 1/29/2006	
	C93	GENBANK Accession No: NM_002006, dated 10/1/2006	
	C94	GENBANK Accession No: NM_002087, dated 10/18/2005	
	C95	GENBANK Accession No: NM_0021 11, dated 2/19/2006	
	C96	GENBANK Accession No: NM_0021 51, dated 1/8/2006	
	C97	GENBANK Accession No: NM_002231, dated 11/27/2005	
	C98	GENBANK Accession No: NM_002392, dated 3/5/2006	
	C99	GENBANK Accession No: NM_0026 ev 32, dated 8/20/2006	
	C100	GENBANK Accession No: NM_0027 74, dated 2/12/2006	
	C101	GENBANK Accession No: NM_0029 63, dated 2/26/2006	
	C102	GENBANK Accession No: NM_0029 86, dated 11/6/2005	
	C103	GENBANK Accession No: NM_0029 ev 25, dated 8/20/2006	
	C104	GENBANK Accession No: NM_0029 ev 64, dated 10/22/2006	
	C105	GENBANK Accession No: NM_0032 55, dated 3/4/2006	
	C106	GENBANK Accession No: NM_0032 56, dated 3/4/2006	
	C107	GENBANK Accession No: NM_0033 55, dated 1/29/2006	
	C108	GENBANK Accession No: NM_0036 42, dated 9/24/2005	
	C109	GENBANK Accession No: NM_0038 ev 83, dated 10/29/2006	
	C110	GENBANK Accession No: NM_004364, dated 1/29/2006	
	C111	GENBANK Accession No: NM_004395, dated 10/16/2005	
	C112	GENBANK Accession No: NM_0047 95, dated 2/26/2006	

NYI-4181623v1

**EXAMINER  
SIGNATURE**

**DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

<b>Application Number</b>	10/579,500
<b>Filing Date</b>	Sept. 15, 2006
<b>First Named Inventor</b>	Mehta et al.
<b>Art Unit</b>	1642
<b>Examiner Name</b>	Goddard, Laura B.
<b>Attorney Docket No.</b>	10589-096-999

**NON PATENT LITERATURE DOCUMENTS**

	<b>Cite No.</b>	<b>Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.</b>	<b>T</b>
	C113	GENBANK Accession No: NM_0047 97, dated 3/5/2006	
	C114	GENBANK Accession No: NM_0052 51, dated 2/12/2006	
	C115	GENBANK Accession No: NM_0052 52, dated 1/29/2006	
	C116	GENBANK Accession No: NM_0054 ev 17, dated 4/19/2009	
	C117	GENBANK Accession No: NM_0059 31, dated 10/16/2005	
	C118	GENBANK Accession No: NM_006536, dated 9/17/2006	
	C119	GENBANK Accession No: NM_007310, dated 1/29/2006	
	C120	GENBANK Accession No: NM_0187 ev 27, dated 3/1/2009	
	C121	GENBANK Accession No: NM_0204 15, dated 1/29/2006	
	C122	GENBANK Accession No: NM_0326 11, dated 3/4/2006	
	C123	GENBANK Accession No: NM_053056, dated 2/26/2006	
	C124	GENBANK Accession No: NM_0784 67, dated 3/5/2006	
	C125	GENBANK Accession No: NM_0807 04, dated 3/2/2006	
	C126	GENBANK Accession No: NM_0807 05 , dated 3/2/2006	
	C127	GENBANK Accession No: NM_0807 06, dated 3/2/2006	
	C128	GENBANK Accession No: NM_080881, dated 10/17/2005	
	C129	GENBANK Accession No: NM_138712, dated 3/5/2006	
	C130	GENBANK Accession No: NM_1389 92, dated 2/12/2006	
	C131	GENBANK Accession No: NM_1393 ev 17, dated 10/29/2006	
	C132	GENBANK Accession No: S48568, dated 4/17/2002	
	C133	GENBANK Accession No: U22431, dated 6/28/1995	
	C134	GENBANK Accession No: U25676, dated 7/20/1995	
	C135	GENBANK Accession No: X00588.1, dated 3/30/1995	
	C136	GENBANK Accession No: X01394, dated 3/21/1995	
	C137	GENBANK Accession No: X16302, dated 4/18/2005	
	C138	GENBANK Accession No: XM_001831, dated 5/8/2002	
	C139	GENBANK Accession No: XM_003061, dated 5/8/2002	

NYI-4181623v1

**EXAMINER  
SIGNATURE**

**DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

<b>Application Number</b>	10/579,500
<b>Filing Date</b>	Sept. 15, 2006
<b>First Named Inventor</b>	Mehta et al.
<b>Art Unit</b>	1642
<b>Examiner Name</b>	Goddard, Laura B.
<b>Attorney Docket No.</b>	10589-096-999

**NON PATENT LITERATURE DOCUMENTS**

	<b>Cite No.</b>	<b>Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.</b>	<b>T</b>
	C140	GENBANK Accession No: XM_003751, dated 10/16/2001	
	C141	GENBANK Accession No: XM_015547, dated 8/1/2002	
	C142	GENBANK Accession No: XM_589987, dated 9/30/2005	
	C143	GIL et al., 1996, "Multiple regions of the <i>Arabidopsis</i> SAUR-AC1 gene control transcript abundance: the 3' untranslated region functions as an mRNA instability determinant." EMBO J 15:1678-1686	
	C144	GOODWIN et al., 1993, "Translational regulation of tra-2 by its 3' untranslated region controls sexual identity in <i>C. elegans</i> ." Cell 75:329-339	
	C145	GOODWIN et al., 1997, "A genetic pathway for regulation of tra-2 translation" Develop. 124:749-758	
	C146	GREEN et al., 2002, "Crystallization and characterization of Smaug: a novel RNA-binding motif." Biochem. Biophys. Res. Commun. 297(5):1085-1088	
	C147	GRENS et al., 1990, "The 5'- and 3'-untranslated regions of ornithine decarboxylase mRNA affect the translational efficiency." J Biol. Chem. 265:11810-11816	
	C148	GUHANIYOGI & BREWER, 2001, "Regulation of mRNA stability in mammalian cells." Gene 265(1-2):11-23	
	C149	HAAG & KIMBLE, 2000, "Regulatory elements required for development of caenorhabditis elegans hermaphrodites are conserved in the tra-2 homologue of <i>C. remanei</i> , a male/female sister species" Genetics 155(1):105-116	
	C150	HEATON et al., 1998, "Cyclic nucleotide regulation of type-1 plasminogen activator-inhibitor mRNA stability in rat hepatoma cells. Identification of cis-acting sequences." J Biol. Chem. 273:14261-14268	
	C151	HUANG et al., 1990, "Intervening sequences increase efficiency of RNA 3' processing and accumulation of cytoplasmic RNA", Nucl. Acids Res. 18:937-947	
	C152	HUBERT et al., 1996, "RNAs mediating cotranslational insertion of selenocysteine in eukaryotic selenoproteins" Biochimie 78(7):590-596	
	C153	HUEZ et al., 1998, "Two Independent Internal Ribosome Entry Sites are Involved in Translation Initiation of Vascular Endothelial Growth Factor mRNA." Molec & Cell Biol. 18(11):6178-6190	
	C154	HYDER et al., 2000, "Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor," Cancer Res 60:3183-3190	
	C155	IIDA et al., 2002, "Vascular endothelial growth factor gene expression in a retinal pigmented cell is up-regulated by glucose deprivation through 3' UTR" Life Sciences 71:1607-1614	
	C156	IKEMURA AND OKEKI, 1983, "Codon usage and transfer RNA contents: organism-specific codon-choice patterns in reference to the isoacceptor contents." Cold Spring Harbor Symp. Quant. Biol. 47:1087-1097	
	C157	IKEMURA, 1985, "Codon usage and tRNA content in unicellular and multicellular organisms." Mol. Biol. Evol., 2(1):13-34	
	C158	ISMAIL et al., 2000, "Split-intron retroviral vectors: enhanced expression with improved safety", J. Virol. 74:2365-2371	

NYI-4181623v1

**EXAMINER  
SIGNATURE**

**DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)	<b>Application Number</b>	10/579,500
	<b>Filing Date</b>	Sept. 15, 2006
	<b>First Named Inventor</b>	Mehta et al.
	<b>Art Unit</b>	1642
	<b>Examiner Name</b>	Goddard, Laura B.
	<b>Attorney Docket No.</b>	10589-096-999

### NON PATENT LITERATURE DOCUMENTS

	<b>Cite No.</b>	<b>Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.</b>	<b>T</b>
	C159	JAN et al., 1997, "Conservation of the C.elegans tra-2 3'UTR translational control." EMBO J 16(20):6301-6313	
	C160	JAN et al., 1999, "The STAR protein, GLD-1, is a translational regulator of sexual identity in Caenorhabditis elegans." EMBO J. 18:258-269	
	C161	KAKEGAWA et al., 2002, "Rapamycin induces binding activity to the terminal oligopyrimidine tract of ribosomal protein mRNA in rats." Arch Biochem Biophys 402(1):77-83	
	C162	KASTELIC et al., 1996, "Induction of rapid IL-1 beta mRNA degradation in THP-1 cells mediated through the AU-rich region in the 3'UTR by a radicicol analogue." Cytokine 8: 751-761	
	C163	KEDERSHA et al., 2002, "Stress Granules: Sites of mRNA Triage that regulate mRNA stability and translatability." Biochem Soc. Transact. 30(6):963-969	
	C164	KEENE & TENENBAUM, 2002, "Eukaryotic mRNPs may represent posttranscriptional operons" Mol. Cell. 9:1161-1167	
	C165	KELLY et al., 1996, "Reconciliation of the X-ray and NMR structures of the thrombin-binding aptamer d(GGTGGTGTGGTTGG)." J. Mol. Biol. 256:417-422	
	C166	KEMENY et al., 1998, "The tetravalent guanylyldrazone CNI-1493 blocks the toxic effects of interleukin-2 without diminishing antitumor efficacy." Proc. Natl. Acad. Sci. USA 95: 4561-4566	
	C167	KIM et al., 2002, "The human elongation factor 1 alpha (EF-1 alpha) first intron highly enhances expression of foreign genes from the murine cytomegalovirus promoter." J. Biotechnol. 93(2):183-187	
	C168	KIMBLE, 1988, "fog-2, a germ-line-specific sex determination gene required for hermaphrodite spermatogenesis in Caenorhabditis elegans." Genetics, 119:43-61	
	C169	KLAUSNER et al., 1993, "Regulating the fate of mRNA: The control of cellular iron metabolism" Cell 72:19-28	
	C170	KLEMAN-LEYER et al., 1997, "Properties of H. volcanii tRNA intron endonuclease reveal a relationship between the archaeal and eucaryal tRNA intron processing systems." Cell., 89:839-847	
	C171	KOBAYASHI et al., 1998, "Characterization of the 3' untranslated region of mouse DNA topoisomerase II $\alpha$ mRNA," Gene 215:329-337	
	C172	KOELLER et al., 1991, "Translation and the stability of mRNAs encoding the transferrin receptor and c-fos." Proc. Natl. Acad. Sci. 88:7778	
	C173	KOZAK et al., 1986, "Influences of mRNA Secondary structure on initiation by Eukaryotic Ribosomes" Proc. Natl. Acad. Sci 83:2850-2854	
	C174	LAGNADO et al., 1994, "AUUUA is not sufficient to promote Poly(A) shortening and degradation of an mRNA: the functional sequence within the AU-rich elements may be UUAUUUA(U/A) (U/A)" Mol. Cell. Biol. 14: 7984-7995	
	C175	LAI et al., 1999, "Evidence that Tristetraprolin binds to AU-Rich Elements and promotes the Deadenylation and Destabilization of Tumor Necrosis Factor Alpha mRNA" Molec & cell. Biol. 19(6):4311-4323	
	C176	LE & MAIZEL, 1989, "A method for assessing the statistical significance of RNA folding" J. Theor Biol. 138:495-510	

NYI-4181623v1

**EXAMINER  
SIGNATURE**
**DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)	<b>Application Number</b>	10/579,500
	<b>Filing Date</b>	Sept. 15, 2006
	<b>First Named Inventor</b>	Mehta et al.
	<b>Art Unit</b>	1642
	<b>Examiner Name</b>	Goddard, Laura B.
	<b>Attorney Docket No.</b>	10589-096-999

### NON PATENT LITERATURE DOCUMENTS

	Cite No.	Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C177	LEMM et al., 2002, "Regulation of c-myc mRNA decay by translational pausing in a coding region instability determinant", Mol. Cell. Biol. 22:3959-3969	
	C178	LEVY et al., 1995, "Sequence and functional characterization of the terminal exon of the human insulin receptor gene." Biochem Biophys Acta 1263:253-257	
	C179	LEVY et al., 1996, "Post-transcriptional regulation of vascular endothelial growth factor by hypoxia." J. Biol. Chem. 271:2746-2753	
	C180	LEVY et al., 1998, "Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR." J Biol. Chem. 273(11):6417-6423	
	C181	LEWIS et al., 1998, "Mapping of a minimal AU-rich sequence required for lipopolysaccharide-induced binding of a 55-kDa protein on tumor necrosis factor- $\alpha$ mRNA." J Biol. Chem. 273:13781-13786	
	C182	INTERNATIONAL Search Report dated July 13, 2005 in the PCT Application No. PCT/US04/26309 filed 8/16/04	
	C183	SACHS & GEBALLE, 2006, "Downstream control of upstream open reading frames." 20:915-921	
	C184	WRITTEN OPINION, dated May 17, 2006 in the PCT Application No. PCT/US04/038496 filed Nov. 17, 2004	
	C185	MACAYA et al., 1993, "Thrombin-binding DNA aptamer forms a unimolecular quadruplex structure in solution." Proc. Natl. Acad. Sci. 90:3745-3749	
	C186	MILLER et al., 1998, "The Vascular Endothelial Growth Factor mRNA contains an Internal Ribosome Entry Site." FEBS Letters 434:417-420	
	C187	MUHLRAD et al., 1995, "Turnover mechanisms of the stable yeast PGK1 mRNA." Mol. Cell. Biol. 15(4):2145-2156	
	C188	MUKHERJEE et al., 2002, "The mammalian exosome mediates the efficient degradation of mRNAs that contain AU-rich elements." EMBO J. 21:165-174	
	C189	NANBRU et al., 1995, "Alternative translation of the proto-oncogene c-myc by an internal ribosome entry site." J. Biol. Chem. 272:32061-32066	
	C190	NANBU et al., 1994, "Multiple instability-regulating sites in the 3' untranslated region of the urokinase-type plasminogen activator mRNA." Mol. Cell. Biol. 14:4920-4928	
	C191	NISHIMORI et al., 2004, "Involvement of the 3'-untranslated region of cyclooxygenase-2 gene in its post-transcriptional regulation through the glucocorticoid receptor", Life Sciences 74:2505-2513	
	C192	OH et al., 1992, "Homeotic gene Antennapedia mRNA contains 5'-noncoding sequences that confer translational initiation by internal ribosome binding." Genes Dev 6:1643-1653	
	C193	OSTARECK-LEDERER et al., 2002, "c-Src-mediated phosphorylation of hnRNP K drives translational activation of specifically silenced mRNAs" Mol. Cell. Biol. 22(13):4535-4543	
	C194	PAYNTON & BACHVAROVA, 1994, "Polyadenylation and deadenylation of maternal mRNAs during oocyte growth and maturation in the mouse" Mol. Reprod. Dev 37(2): 172-180	
	C195	PELLETIER & SONEBERG, 1988, "Internal initiation of translation of eukaryotic mRNA directed by a sequence derived from poliovirus RNA" Nature 334:320-325	
	C196	PETERLIN et al., 1993, "Tat Trans-Activator." In: Human Retroviruses; Cullen, Ed.; Oxford University Press: New York, pp. 75-100	

NYI-4181623v1

**EXAMINER  
SIGNATURE**
**DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)	<b>Application Number</b>	10/579,500
	<b>Filing Date</b>	Sept. 15, 2006
	<b>First Named Inventor</b>	Mehta et al.
	<b>Art Unit</b>	1642
	<b>Examiner Name</b>	Goddard, Laura B.
	<b>Attorney Docket No.</b>	10589-096-999

### NON PATENT LITERATURE DOCUMENTS

	Cite No.	Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C197	PIECYK et al., 2000, "TIA-1 is a translational silencer that selectively regulates the expression of TNF-alpha" EMBO J. 19:4154	
	C198	INTERNATIONAL Search Report, dated Nov. 6, 2007 of PCT/US04/20751 filed 6/28/04	
	C199	RAJAGOPALAN & MALTER, 2000, "Growth factor-mediated stabilization of amyloid precursor protein mRNA is mediated by a conserved 29-nucleotide sequence in the 3'-untranslated region." J. Neurochem. 74(1):52-59	
	C200	RAPELLA et al., 2002, "Flavopiridol inhibits vascular endothelial growth factor production induced by hypoxia or picolinic acid in human neuroblastoma." Int J. Cancer 99:658-664	
	C201	RAUGHT et al. 2000, "Regulation of ribosomal recruitment in eukaryotes" in: "Translational Control of Gene Expression." Sonenberg, Hershey and Mathews, eds. Cold Spring Harbor Laboratory Press, Ch. 6. pp. 245-293	
	C202	REINMANN et al., 2002, "Suppression of 15-lipoxygenase synthesis by hnRNP E1 is dependent on repetitive nature of LOX mRNA 3'-UTR control element DICE." J. Mol. Biol. 315(5):965-974	
	C203	WRITTEN Opinion of the International Searching Authority dated July 11/6/07 in the PCT Application No. PCT/US04/020751 filed 6/28/04	
	C204	ROGERS et al., 2002, "An iron-responsive element type II in the 5'-untranslated region of the Alzheimer's amyloid precursor protein transcript." J. Biol. Chem. 277(47):45518-45528	
	C205	SACHS, 1993, "Messenger RNA degradation in eukaryotes." Cell 74:413-421	
	C206	SAMBROOK et al., 1989, "Standard protocol for calcium phosphate-mediated transfection of adherent cells." Molec. Cloning 16.33 - 16.37	
	C207	SARKAR & HOPPER., 1998, "tRNA nuclear export in <i>Saccharomyces cerevisiae</i> : In situ hybridization analysis." Mol. Biol. Cell 9:3041-3055	
	C208	SAVANT-BHONSALE et al., 1992, "Evidence for instability of mRNAs containing AUUUA motifs mediated through translation-dependent assembly of a > 20S degradation complex" Genes Dev. 6:1927-1939	
	C209	SAXENA et al., 1992, "Angiogenin is a cytotoxic, tRNA-specific ribonuclease in the RNase A superfamily." J. Biol. Chem. 267(30):21982-21986	
	C210	SCHLATTER & FUSSENEGGER, 2003, "Novel CNBP- and La-based translation control systems for mammalian cells." Biotechnol Bioeng. 81(1):1-12	
	C211	SCHULTZE et al., 1994, "Three-dimensional solution structure of the thrombin-binding DNA aptamer d(GGTTGGTGTGGTTGG)." J. Mol. Biol. 235:1532-1547	
	C212	SHAW & KAMEN, 1986, "A conserved AU sequence from the 3' untranslated region of GM-CSF mRNA mediates selective mRNA degradation." Cell 46:659-667	
	C213	SHYU et al., 1991, "Two distinct destabilizing elements in the c-fos message trigger deadenylation as a first step in rapid mRNA decay." Genes Dev 5:221-231	
	C214	STEBBINS-BOAZ et al., 1996, "CPEB controls the cytoplasmic polyadenylation of cyclin, Cdk2 and c-mos mRNAs and is necessary for oocyte maturation in <i>Xenopus</i> ." EMBO J. 15(10):2582-2592	
	C215	STEIN et al., 1998, "Translation of vascular endothelial growth factor mRNA by internal ribosome entry: implications for translation under hypoxia" Mol. Cell. Biol. 18L:3112-3119	

NYI-4181623v1

**EXAMINER  
SIGNATURE**
**DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)	<b>Application Number</b>	10/579,500
	<b>Filing Date</b>	Sept. 15, 2006
	<b>First Named Inventor</b>	Mehta et al.
	<b>Art Unit</b>	1642
	<b>Examiner Name</b>	Goddard, Laura B.
	<b>Attorney Docket No.</b>	10589-096-999

### NON PATENT LITERATURE DOCUMENTS

	Cite No.	Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C216	STOECKLIN et al., 1994, "Functional Hierarchy of AUUUA Motifs in Mediating Rapid Interleukin-3 mRNA decay." J Biol. Chem. 269:28591-28597	
	C217	STOECKLIN et al., 2003, "A constitutive Decay Element Promotes Tumor Necrosis factor alpha mRNA Degradation via an AU-Rich Element-Independent Pathway." Molec & cell. Biol. 23(10):3506-3515	
	C218	STOLLE et al., 1988, "Cellular Factor affecting the stability of $\beta$ -globin mRNA." Gene 62:65-74	
	C219	STONELEY, 1998, "C-Myc 5' untranslated region contains an internal ribosome entry segment" Oncogene 16:423-428	
	C220	SULLIVAN et al., 1996, "Mutational analysis of the DST element in tobacco cells and transgenic plants: Identification of residues critical for mRNA instability," RNA 2:308-315	
	C221	TAY et al., 2000, , "The control of cyclin B1 mRNA translation during mouse oocyte maturation." Dev. Biol. 221(1):1-9	
	C222	THIELE et al., 1999, "Expression of leukocyte-type 12-lipoxygenase and reticulocyte-type 15-lipoxygenase in rabbits" Adv Exp Med Biol. 447:45-61	
	C223	THOLANIKUNNEL & MALBORN, 1997, "A 20-nucleotide (A + U)-rich element of beta2-adrenergic receptor (beta2AR) mRNA mediates binding to beta2AR-binding protein and is obligate for agonist-induced destabilization of receptor mRNA." J. Biol. Chem. 272:11471	
	C224	THOMPSON et al., 2000, "Rapid deadenylation and Poly(A)-dependent translational repression mediated by the Caenorhabditis elegans tra-2 3' untranslated region in Xenopus embryos." Mol. Cell. Biol. 20(6):2129-2137	
	C225	TISCHER et al., 1991, "The human gene for vascular endothelial Growth Factor." The J Biol Chem. 266(18):11947-11954	
	C226	TRIFILLIS et al., 1999, "Finding the right RNA: identification of cellular mRNA substrates for RNA-binding proteins." RNA 5:1071-1082	
	C227	WRITTEN Opinion of the International Searching Authority dated July 13, 2005 in the PCT Application No. PCT/US04/26309 filed 8/16/04	
	C228	TROTTA et al., 2003, "BCR/ABL activates mdm2 mRNA translation via the Ia antigen." Cancer cell 3:145-160	
	C229	TROTTA, "Gene Expression" Revised Background Draft	
	C230	INTERNATIONAL Preliminary Report on Patentability, dated 11/19/07 in the PCT Application No. PCT/US04/020751	
	C231	VAGNER et al., 1995, "Alternative translation of human fibroblast growth factor 2 mRNA occurs by internal entry of ribosomes." Mol. Cell. Biol. 15:35-44	
	C232	VAGNER et al., 2001, "Irresistible IRES. Attracting the translation machinery to internal ribosome entry sites." EMBO Reports 2:893	
	C233	VOLAREVIC et al., 2000, "Proliferation, but not growth blocked by conditional deletion of 40S ribosomal protein S6." Science 288:2045-2047	
	C234	WANG et al., 1993, "A DNA aptamer which binds to and inhibits thrombin exhibits a new structural motif for DNA." Biochem. 32(8):1899-1904	

NYI-4181623v1

**EXAMINER  
SIGNATURE**
**DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)	<b>Application Number</b>	10/579,500
	<b>Filing Date</b>	Sept. 15, 2006
	<b>First Named Inventor</b>	Mehta et al.
	<b>Art Unit</b>	1642
	<b>Examiner Name</b>	Goddard, Laura B.
	<b>Attorney Docket No.</b>	10589-096-999

### NON PATENT LITERATURE DOCUMENTS

	<b>Cite No.</b>	<b>Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.</b>	<b>T</b>
	C235	WANG et al., 2003, "Human SP-A 3'-UTR variants mediate differential gene expression in basal levels and in response to dexamethasone." Am J Physiol, Lung Cell & Molec Physiol. 284(5):L738-L748	
	C236	WELLS et al., 1998, "Circularization of mRNA by eukaryotic translation initiation factors." Mol. Cell. 2:135-140	
	C237	WESTMARK & MALTER, 2001, "Extracellular-regulated kinase controls beta-amyloid precursor protein mRNA decay" Brain Res Mol. Brain. Res 90(2):193-201	
	C238	WILKUND et al., 2002, "Inhibition of translation by UAUUUUAU and UAUUUUUUAU motifs of the AU-rich RNA instability element in the HPV-1 late 3' untranslated region." J. Biol. Chem. 277:40462	
	C239	WINSTALL et al., 1995, "Rapid mRNA degradation mediated by the c-fos 3' AU-rich element and that mediated by the granulocyte-macrophage colony-stimulating factor 3' AU-rich element occur through similar polysome-associated mechanisms" Mol. Cell. Biol. 15:3796-3804	
	C240	WORTHINGTON et al., 2002, "RNA binding properties of the AU-rich element-binding recombinant Nup475/TIS11/tristetraprolin protein." J. Biol. Chem. 277: 48558-48564	
	C241	XU et al., 1997, "Modulation of the fate of cytoplasmic mRNA by AU-rich elements: key sequence features controlling mRNA deadenylation and decay." Mol. Cell. Biol. 17:4611-4621	
	C242	YAMAZAKI et al., 2003, "HIF-1 Dependent VEGF Reporter Gene Assay by a Stable Transformant of CHO cells." Biol. Pharm. Bull. 26(4):417-420	
	C243	YE et al., 1997, "Ultrabithorax and Antennapedia 5' untranslated regions promote developmentally regulated internal translation initiation" Mol. Cell. Biol. 17:1714-1721	
	C244	ZAIDI & MALTER, 1995, "Nucleolin and heterogeneous nuclear ribonucleoprotein C proteins specifically interact with the 3'-untranslated region of amyloid protein precursor mRNA." J. Biol. Chem. 271(29):17292-17298	
	C245	ZHANG et al., 1995, "Identification and characterization of a sequence motif involved in nonsense-mediated mRNA decay" Mol. Cell. Biol. 15:2231-2244	
	C246	ZHANG et al., 1996, "An enhanced green fluorescent protein allows sensitive detection of gene transfer in mammalian cells." BBRC 227:707-711	
	C247	ZHANG et al., 1997, "Gene expression profiles in normal and cancer cells." Science 276:1268-1272	
	C248	ZHU et al., 2001, "Binding of the La autoantigen to the 5' untranslated region of a chimeric human translation elongation factor 1A reporter mRNA inhibits translation in vitro." Biochim. Biophys Acta 1521(1-3):19-29	
	C249	ZUBIAGA et al., 1995, "The nonamer UUAUUUAUU is the key AU-rich sequence motif that mediates mRNA degradation," Mol. Cell. Biol. 15(4):2219-2230	
	C250	AMENDMENT filed 4/3/08 in U.S. Serial No. 10/895,393	
	C251	OFFICE Action mailed 10/4/07 in U.S. Serial No. 10/895,393	
	C252	RESPONSE to Notice of Non-Compliant Amendment filed 7/9/07 in U.S. Serial No. 10/895,393	
	C253	RESTRICTION Requirement mailed 12/28/06 in U.S. Serial No. 10/895, 393	

NYI-4181623v1

**EXAMINER  
SIGNATURE**
**DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

<b>Application Number</b>	10/579,500
<b>Filing Date</b>	Sept. 15, 2006
<b>First Named Inventor</b>	Mehta et al.
<b>Art Unit</b>	1642
<b>Examiner Name</b>	Goddard, Laura B.
<b>Attorney Docket No.</b>	10589-096-999

**NON PATENT LITERATURE DOCUMENTS**

	<b>Cite No.</b>	<b>Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.</b>	<b>T</b>
	C254	RESPONSE to Restriction Requirement filed 4/25/07 in U.S. Serial No. 10/895, 393	
	C255	FINAL Office Action mailed 12/16/08 in U.S. Serial No. 10/895,393	
	C256	REQUEST for Continued Examination and Amendment, dated 06/16/09 in U.S. Serial No. 10/895,393	
	C257	PRELIMINARY Amendment filed 10/23/06 in U.S. Serial No. 10/543, 033	
	C258	RESTRICTION Requirement mailed 5/16/08 in U.S. Serial No. 10/543, 033	
	C259	RESPONSE to Restriction Requirement filed 11/17/08 in U.S. Serial No. 10/543, 033	
	C260	OFFICE Action mailed 2/20/09 in U.S. Serial No. 10/543, 033	
	C261	REQUIREMENT for Restriction/Election, dated January 11, 2007 of U.S. Application No: 10/851,074 filed May 24, 2004	
	C262	AMENDMENT and Response to Restriction/Election dated May 11, 2007 of U.S. Application No: 10/851,074 filed May 24, 2004	
	C263	NON FINAL Rejection dated September 7, 2007 of of U.S. Application No: 10/851,074 filed May 24, 2004	
	C264	AMENDMENT and Response to Non-Final Rejection dated March 4, 2008 of U.S. Application No: 10/851,074 filed May 24, 2004	
	C265	NON FINAL Rejection dated July 10, 2008 of of U.S. Application No: 10/851,074 filed May 24, 2004	
	C266	NON FINAL Rejection dated October 23, 2008 of of U.S. Application No: 10/851,074 filed May 24, 2004	
	C267	AMENDMENT and Response to Non-Final Rejection dated April 22, 2009 of U.S. Application No: 10/851,074 filed May 24, 2004	
	C268	SUPPLEMENTAL European Search Report, dated 11/19/08, issued in EP 04809465.0 (EP1761638	
	C269	SUPPLEMENTAL Partial European Search Report, dated 5/30/2008, issued in EP 04781055.1 (EP 1786933)	
	C270	INTERNATIONAL Search Report dated July 14, 2008 in the PCT Application No. PCT/US04/01643 filed January 21, 2004	
	C271	WRITTEN OPINION of the International Searching Authority dated July 14, 2008 in the PCT Application No. PCT/US04/01643 filed January 21, 2004	
	C272	INTERNATIONAL Preliminary Report on Patentability, dated 1/23/07 in the PCT Application No. . PCT/US04/26309 filed 8/16/04	

NYI-4181623v1

**EXAMINER  
SIGNATURE**

**DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.